YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee. Continue Reading
Halozyme Therapeutics HALO announced that a Dutch patent court has issued a ruling in its favor in a patent dispute with Merck MRK over Keytruda's subcutaneous (SC) formulation. The court found that Merck's Keytruda SC infringes one of Hal…
Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee. Continue Reading
European equities traded in the US as American depositary receipts fell late Thursday morning with t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response. Continue Reading
Argenx SE(NASDAQ:ARGX) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for another therapy. Phase 2 FB102 Celiac Disea…
Argenx (ARGX) will discontinue a phase 3 study of efgartigimod subcutaneous in adults with moderate- PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's par…
Investing.com -- Shares in Belgian biotech argenx tumbled over 16% on Thursday after it said it would stop a late-stage trial of its drug efgartigimod in Sjögren's disease because an interim analysis showed it was unlikely to succeed. Befo…
argenx SE Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to adva…
argenx SE October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous…
European equities traded in the US as American depositary receipts fell late Wednesday morning with PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Halozyme Therapeutics HALO announced that it has expanded the global collaboration and license agreement with argenx ARGX to develop and commercialize its ENHANZE technology with two additional exclusive targets. The expanded collaboration…
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity…
European equities traded in the US as American depositary receipts were trending higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
European equities traded in the US as American depositary receipts were trending lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
argenx SE New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patient…
Ginkgo generates antibody data at scale and trains models for drug manufacturability and developability. Apheris' federated infrastructure enables participating pharmaceutical companies to use those models and further fine-tune them on the…
European equities traded in the US as American depositary receipts were tracking slightly lower Thur PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer ter…
argenx has delivered a striking share-price run over the past few years, which naturally puts the microscope on what investors are paying for its earnings today. With the stock coming off a strong multi‑year performance but some recent sof…
Stock Market Today: The Dow Jones index falls Wednesday after the Nasdaq set new highs Tuesday. Micron and Sandisk drop in morning trade. Continue Reading
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts. Continue Reading
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts. Continue Reading
On September 17, Halozyme (NASDAQ:HALO) priced $1.3 billion of convertible senior notes due 2033, an offering that grew from an originally planned $1.05 billion as demand came in. The notes carry a 1.50% coupon and convert into stock at $1…
Argenx (NASDAQ: ARGX) has been a solid winner for investors over the last 12 months, with its shares rising by roughly 30%. Wall Street thinks that the biotech stock can go even higher. The consensus one-year price target for Argenx reflec…
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opport…
argenx SE September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appoi…
European equities traded in the US as American depositary receipts were tracking lower late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Scientist-led competitive selection deepens BenchSci's presence in European biopharma TORONTO, September 02, 2026--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-y…
To say that Argenx (NASDAQ: ARGX) is growing is an understatement. The drugmaker has delivered an impressive 18 consecutive quarters of revenue growth. Its sales soared 60% year over year in the second quarter of 2026 and 17% sequentially.…
argenx SE September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences i…
Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain. A 209.7% return over 5 years points to a stock where exp…
argenx (ENXTBR:ARGX) is back in focus after reporting positive topline results from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, a rare muscle disease with limited targeted treatment options. argenx shares have reac…
argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment…